{"category":{"kind":"industry","slug":"gene-editing","name":"Gene Editing","tagline":null,"description":null,"synonyms":[],"target_queries":[],"added_via":"web","added_at":"2026-10-26T10:18:28.457Z","updated_at":"2026-10-26T10:18:28.457Z","example":false,"profile_url":"/industries/gene-editing","is_stub":true,"member_count":2,"member_counts":{"company":2}},"members":[{"listing_type":"company","name":"Specific Biologics","slug":"specific-biologics","tagline":"Toronto biotech developing Dualase genome editors as in vivo therapies, starting with C9ORF72 ALS","description":"Specific Biologics is a Toronto-based biotechnology company developing in vivo genome-editing medicines built on its Dualase editors. Dualase uses a two-site mechanism, pairing an engineered Cas domain with an I-TevI nuclease domain, to enable precise removal, repair and insertion of DNA sequences, with an initial focus on removing expanded DNA repeats. Its pipeline spans CNS, lung and liver indications, delivered by single AAV or encapsulated all-RNA formats. In November 2026 it announced an oversubscribed $35 million Series A led by Hatteras Venture Partners to take its Dualase candidate into an adaptive Phase I/II trial for C9ORF72-associated ALS.","url":"https://www.specificbiologics.com/","is_stealth":false,"normalized_domain":"specificbiologics.com","normalized_url_key":"specificbiologics.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://static.wixstatic.com/media/d0f7a9_acfb3ad5a6f94f91b217d095941c3487~mv2.png","links":[],"entry_points":[{"kind":"homepage","url":"https://www.specificbiologics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.specificbiologics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"f12f6525-511a-4d8c-9c84-e62bd77de12e"},"categories":["Biotech","Gene Editing","Therapeutics"],"stage":null,"founded_year":null,"location":"Toronto, Ontario, Canada","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/specific-biologics","contact_email":null,"added_at":"2026-11-03T13:19:24.032Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-11-03T13:23:00.623Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"gene-editing","name":"Gene Editing","note":null,"profile_url":"/industries/gene-editing"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-11-03T13:19:24.032Z","updated_at":"2026-11-03T13:19:24.032Z"}},{"listing_type":"company","name":"DropGenie","slug":"dropgenie","tagline":"Miniaturized CRISPR gene editing workflows for primary cells","description":"DropGenie is a Montreal and Boston biotechnology company that miniaturizes gene editing workflows on a digital microfluidics chip. Its platform runs high-throughput CRISPR edits directly on primary patient cells while using far fewer cells and reagents than conventional methods, aiming to lower costs and speed up turnaround for cell therapy, functional genomics and AI-driven discovery. Its seed+ round was led by Skeleton Key with Merck Global Health Innovation Fund, CQDM, Real Ventures and Anges Québec, and BDC Capital's Thrive Fund later joined, bringing the round to US$5M.","url":"https://dropgenie.com/","is_stealth":false,"normalized_domain":"dropgenie.com","normalized_url_key":"dropgenie.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://dropgenie.com/wp-content/uploads/2025/04/cropped-favicon_dropgenie-1-192x192.png","links":[{"label":"BetaKit: DropGenie raises US$5M backed by BDC","url":"https://betakit.com/dropgenie-raises-5-million-usd-backed-by-bdc-to-speed-up-biological-discovery/"}],"entry_points":[{"kind":"homepage","url":"https://dropgenie.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://dropgenie.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"02bafe89-63d6-4d23-b10d-b604486e1571"},"categories":["Biotech","Gene Editing","Life Sciences Tools"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-10-26T10:18:28.457Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-26T10:19:15.335Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"gene-editing","name":"Gene Editing","note":null,"profile_url":"/industries/gene-editing"},{"kind":"industry","slug":"life-sciences-tools","name":"Life Sciences Tools","note":null,"profile_url":"/industries/life-sciences-tools"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-10-26T10:18:28.457Z","updated_at":"2026-10-26T10:18:28.457Z"}}],"total":2,"limit":50,"offset":0}